Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bendamustine Hydrochloride
/ administration & dosage
Female
Follow-Up Studies
Humans
Lymphoma, B-Cell, Marginal Zone
/ drug therapy
Male
Middle Aged
Prognosis
Remission Induction
Retrospective Studies
Rituximab
/ administration & dosage
Survival Rate
bendamustine
marginal zone lymphoma
rituximab
untreated
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
05
2020
revised:
08
06
2020
accepted:
23
06
2020
pubmed:
1
7
2020
medline:
3
11
2020
entrez:
29
6
2020
Statut:
ppublish
Résumé
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and various regimens with chemo-immunotherapy can be used. Rituximab plus bendamustine (BR) is an effective and manageable treatment option for patients affected by indolent non-Hodgkin lymphoma. The aim of this monocentric retrospective study was to analyze the effectiveness and safety of the use of BR regimen in MZL patients in first line in daily clinical practice. The treatment schedule was rituximab at the dose of 375 mg/m
Substances chimiques
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
487-492Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Zinzani PL, Broccoli A. Marginal zone B-cell lymphomas. In: Kaushansky K, Lichtman MA, Prchal JT, et al., eds. Williams Hematology. 9th ed. New York: McGraw Hill; 2016:1663-1669.
Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options in Oncol. 2019;20:90.
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857-877.
Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:144-148.
Stathis A, Chini C, Bertoni F, et al. Long-term outcome following helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20:1086-1093.
Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30:2988-2994.
Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013;122:1350-1357.
Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1:104-111.
Zinzani PL, Pellegrini C, Broccoli A, et al. Fludarabine-mitoxantrone-rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. Hematol Oncol. 2015;33:141-146.
Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus Chlorambucil versus either Chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35:1905-1912.
Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145:741-748.
Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a dis-tinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-317.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-1210.
Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944-2952.
Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130:1772-1774.
Cencini E, Fabbri A, Schiattone L, Bocchia M. Efficacy and safety of rituxiamb plus bendamustine in gastric marginal zone lymphoma. Leuk Lymphoma. 2019;60:833-835.
Castelli R, Bergamaschini L, Deliliers GL. First-line treatment with bendamustine and rituximab, in patients with intermediate−/high-risk splenic marginal zone lymphomas. Med Oncol. 2017;35:1076-1081.
Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183:755-765.
Laribi K, Tempescul A, Ghnava H, et al. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. Hematol Oncol. 2017;35:536-541.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2012;91:543-551.